LIN BIOSCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.1 TWD | +18.90% |
|
+25.81% | -18.33% |
| Apr. 23 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,213 | 1,815 | 6,987 | 12,832 | 12,583 | 8,946 |
| Enterprise Value (EV) 1 | 1,945 | 1,766 | 5,900 | 12,027 | 10,985 | 5,728 |
| P/E ratio | -16 x | -7.72 x | -41.7 x | -29.4 x | -39.8 x | -12.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -12.6 x | -7.46 x | -30.1 x | -35.7 x | -24.8 x | -5.31 x |
| EV / FCF | -22.9 x | -14 x | 41.5 x | -381 x | -16.7 x | -7.63 x |
| FCF Yield | -4.36% | -7.12% | 2.41% | -0.26% | -5.99% | -13.1% |
| Price to Book | 5.86 x | 12.8 x | 7.66 x | 23.7 x | 10.2 x | 4.03 x |
| Nbr of stocks (in thousands) | 59,500 | 59,500 | 68,500 | 68,990 | 72,319 | 78,476 |
| Reference price 2 | 37.20 | 30.51 | 102.0 | 186.0 | 174.0 | 114.0 |
| Announcement Date | 4/26/19 | 4/30/20 | 4/8/21 | 4/25/22 | 4/25/23 | 4/23/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -154.3 | -236.6 | -195.8 | -336.8 | -442.6 | -1,079 |
| EBIT 1 | -155.6 | -238.2 | -197 | -338.3 | -445.1 | -1,097 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -150.5 | -240 | -174.8 | -490.4 | -477.9 | -1,091 |
| Net income 1 | -138.5 | -235.3 | -151.8 | -434.7 | -313.5 | -687.2 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -2.329 | -3.954 | -2.444 | -6.318 | -4.371 | -9.290 |
| Free Cash Flow 1 | -84.83 | -125.7 | 142.2 | -31.55 | -658.5 | -751 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/26/19 | 4/30/20 | 4/8/21 | 4/25/22 | 4/25/23 | 4/23/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 269 | 49.2 | 1,087 | 805 | 1,599 | 3,218 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -84.8 | -126 | 142 | -31.5 | -658 | -751 |
| ROE (net income / shareholders' equity) | -31% | -90.4% | -28.8% | -70.6% | -42% | -41.1% |
| ROA (Net income/ Total Assets) | -20.7% | -46.2% | -16.8% | -19.7% | -20% | -25.2% |
| Assets 1 | 667.9 | 508.8 | 905 | 2,202 | 1,564 | 2,731 |
| Book Value Per Share 2 | 6.340 | 2.380 | 13.30 | 7.850 | 17.10 | 28.30 |
| Cash Flow per Share 2 | 2.820 | 1.970 | 15.90 | 11.70 | 22.70 | 43.20 |
| Capex 1 | 0.94 | 2.34 | 0.57 | 2.12 | 22.4 | 1.97 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/26/19 | 4/30/20 | 4/8/21 | 4/25/22 | 4/25/23 | 4/23/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -18.33% | 224M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 6696 Stock
- Financials Lin BioScience, Inc.
